2002
Report on the XIV International AIDS Conference.
Abdool Karim SS, Currier J, del Rio C, Feinberg J, Friedland GH, Sax PE, Zuger A. Report on the XIV International AIDS Conference. Infectious Diseases 2002, 14: 77-85. PMID: 12236208.Peer-Reviewed Original Research
1998
Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance
Wainberg M, Friedland G. Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance. JAMA 1998, 279: 1977-1983. PMID: 9643862, DOI: 10.1001/jama.279.24.1977.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsDrug Resistance, MicrobialDrug Therapy, CombinationHIV InfectionsHIV-1HumansPatient CompliancePublic HealthViral LoadVirus SheddingConceptsHuman immunodeficiency virusDrug-resistant variantsDrug-resistant virusesHIV drug resistanceAntiviral therapyPublic health implicationsDrug resistanceGenital secretionsHealth implicationsPublic health importanceAntiretroviral therapyViral burdenAntiretroviral agentsPatient adherenceTreatment failureViral loadImmunodeficiency virusResistant virusesSustained reductionHealth importanceTherapyVirusChild routeBloodSecretion
1996
Stavudine (d4T, Zerit®)
Friedland G, Dunkle L, Cross A. Stavudine (d4T, Zerit®). Advances In Experimental Medicine And Biology 1996, 394: 271-277. PMID: 8815691, DOI: 10.1007/978-1-4757-9209-6_24.Peer-Reviewed Original ResearchConceptsAdvanced HIV-1 infectionEffects of stavudinePrior zidovudine therapyHIV-1 infectionImmunologic deteriorationAcceptable toxicityZidovudine therapyHIV diseaseClinical benefitSuch therapySurrogate markerClinical trialsDrug AdministrationStavudineTherapyBeneficial effectsU.S. FoodPatientsInfectionDiseaseAdministrationProgressionTrials